Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop

Pain Medicine (United States)

Volumn 15, Issue 7, 2014, Pages 1072-1082

  Tamburin, Stefano ^a   Borg, Kristian ^d   Caro, Xavier J ^e   Jann, Stefano ^b   Clark, Alexander J ^f   Magrinelli, Francesca ^a   Sobue, Gen ^g   Werhagen, Lars ^d   Zanette, Giampietro ^c   Koike, Haruki ^g   Späth, Peter J ^h   Vincent, Angela ⁱ   Goebel, Andreas ^j  

^a UNIVERSITY OF VERONA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c PEDERZOLI HOSPITAL   (Italy)

^d DANDERYD HOSPITAL   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DALHOUSIE UNIVERSITY   (Canada)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

Immune system; Immunoglobulin; Immunotherapy; Pain; Pathophysiology; Therapy

Indexed keywords

AUTOANTIBODY; HUMAN IMMUNOGLOBULIN; HUMAN IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; PLACEBO; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ARTICLE; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; FIBROMYALGIA; HUMAN; IMMUNOTHERAPY; MEDICAL EXPERT; MUSCLE WEAKNESS; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE PAIN; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POLIOMYELITIS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; POSTHERPETIC NEURALGIA; POSTPOLIOMYELITIS SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SJOEGREN SYNDROME; UNITED KINGDOM; WORKSHOP;

CHRONIC PAIN; HUMANS; IMMUNOGLOBULIN G;

EID: 84904809555     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12319     Document Type: Article

References (67)

1. Cherubino P, Sarzi-Puttini P, Zuccaro SM, etal. The management of chronic pain in important patient subgroups. Clin Drug Investig 2012;32(suppl 1):35-44.
2. Fine PG. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med 2012;13(suppl 2):S57-66.
3. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-581.
4. Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: Diagnosis and treatment. Pract Neurol 2013;13:292-307.
5. Klein CJ, Lennon VA, Aston PA, etal. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012;79:1136-1144.
6. Goebel A. Immunoglobulin responsive chronic pain. J Clin Immunol 2010;30(suppl 1):S103-108.
7. Kohr D, Singh P, Tschernatsch M, etal. Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain 2011;152:2690-2700.
8. Sommer C, Schafers M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 2001;6:67-72.
9. Ludwig J, Binder A, Steinmann J, etal. Cytokine expression in serum and cerebrospinal fluid in non-inflammatory polyneuropathies. J Neurol Neurosurg Psychiatry 2008;79:1268-1273.
10. Uçeyler N, Rogausch JP, Toyka KV, etal. Differential expression of cytokines in painful and painless neuropathies. Neurology 2007;69:42-49.
11. Uçeyler N, Eberle T, Rolke R, etal. Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007;132:195-205.
12. Uçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: Cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011;12:245.
13. Uçeyler N, Sommer C. Status of immune mediators in painful neuropathies. Curr Pain Headache Rep 2008;12:159-164.
14. Gonzalez H, Khademi M, Andersson M, etal. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 2002;205:9-13.
15. Gonzalez H, Khademi M, Borg K, etal. Intravenous immunoglobulin treatment of the post-polio syndrome: Sustained effects on quality of life variables and cytokine expression after one year follow up. J Neuroinflammation 2012;9:167.
16. Fordyce CB, Gagne D, Jalili F, etal. Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 2008;271:80-86.
17. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008;26:513-533.
18. Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med 2009;10:1476-1480.
19. Thaisetthawatkul P, Dyck PJ. Treatment of diabetic and non diabetic lumbosacral radiculoplexus neuropathy. Curr Treat Options Neurol 2010;12:95-99.
20. Dyck PJB, Windebank AJ. Diabetic and non diabetic lumbosacral radiculoplexus neuropathies: New insights into pathophysiology and treatment. Muscle Nerve 2002;25:477-491.
21. Dyck PJB, O'Brien P, Bosch EP, etal. The multi-centre double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology 2006;66(suppl 2):A191.
22. Kawagashira Y, Watanabe H, Oki Y, etal. Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy. J Neurol Neurosurg Psychiatry 2007;78:899-901.
23. Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev 2012;(6):CD006521.
24. Jann S, Francia A, Fruguglietti ME, etal. Efficacy and safety of intravenous immunoglobulin as adjuvant treatment for refractory neuropathic pain. Results of an open-label, multicenter study. Pain Med 2012;13:1334-1341.
25. Kawagashira Y, Watanabe H, Morozumi S, etal. Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy. J Clin Neurosci 2010;17:1003-1008.
26. Clinicaltrialsregister.eu [Internet]. 2012 March 28-Identifier 2010-023883-42, Randomized, double-blind, placebo controlled trial to evaluate the efficacy of high dose intravenous immunoglobulins in diabetic painful polyneuropathy (DPNP) resistant to conventional therapies. London (UK): European Medicine Agency (EU). 2012. Available at: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023883-42 (accessed May 7, 2013).
27. Mori K, Iijima M, Koike H, etal. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain 2005;128:2518-2534.
28. Kawagashira Y, Koike H, Fujioka Y, etal. Differential, size-dependent sensory neuron involvement in the painful and ataxic forms of primary Sjögren's syndrome associated neuropathy. J Neurol Sci 2012;319:139-146.
29. Morozumi S, Kawagashira Y, Iijima M, etal. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci 2009;279:57-61.
30. Goebel A, Netal S, Schedel R, etal. Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 2002;3:119-127.
31. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009 Feb 18-Identifier NCT00850005, intravenous immunoglobulin (IVIG) for resistant neuropathic pain. 2009. Available at: http://clinicaltrials.gov/show/NCT00850005 (accessed May 9, 2013).
32. Bouhassira D, Attal N, Alchaar H, etal. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
33. Harden RN, Oaklander AL, Burton AW, etal. Complex regional pain syndrome: Practical diagnostic and treatment guidelines. Pain Med 2013;14:180-229.
34. Huygen FJ, De Bruijn AG, De Bruin MT, etal. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm 2002;11:47-51.
35. Goebel A, Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 2012;12:682-686.
36. Goebel A, Baranowski A, Maurer K, etal. Intravenous immunoglobulin treatment of the complex regional pain syndrome: A randomized trial. Ann Intern Med 2010;152:152-158.
37. Clinicaltrialsregister.eu [Internet]. 2012 Sept 14-Identifier 2012-000058-73, A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatment, versus matched placebo plus standard treatment in patients with longstanding complex regional pain syndrome. London (UK): European Medicine Agency (EU). 2012. Available at: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000058-73 (accessed May 12, 2013).
38. Goebel A, Mishbah S, McKiver K, etal. Immunoglobulin maintenance therapy in long-standing complex regional pain syndrome, an open study. Rheumatology 2013;52:2091-2093.
39. Nobile-Orazio E, Cocito D, Jann S, etal. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial. Lancet Neurol 2012;11:493-502.
40. Clauw DJ, Arnold LM, McCarberg BH; Fibro Collaborative. The science of fibromyalgia. Mayo Clin Proc 2011;86:907-911.
41. Salemi S, Rethage J, Wollina U, etal. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003;30:146-150.
42. Koroschetz J, Rehm SE, Gockel U, etal. Fibromyalgia and neuropathic pain-differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurol 2011;11:55.
43. Rasmussen PV, Sindrup SH, Jensen TS, etal. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004;110:461-469.
44. Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology 2008;47:208-211.
45. Caro XJ, Winter E. Evidence of abnormal epidermal nerve fiber density in fibromyalgia. Arthritis Rheum 2008;58:S388.
46. Uçeyler N, Zeller D, Kahn AK, etal. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013;136:1857-1867.
47. Gonzalez H, Olsson T, Borg K. Management of postpolio syndrome. Lancet Neurol 2010;9:634-642.
48. Werhagen L, Borg K. Analysis of long-standing nociceptive and neuropathic pain in patients with post-polio syndrome. J Neurol 2010;257:1027-1031.
49. Gonzalez H, Ottervald J, Nilsson KC, etal. Identification of novel candidate protein biomarkers for the post-polio syndrome-Implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics 2009;71:670-681.
50. Gonzalez H, Khademi M, Andersson M, etal. Prior poliomyelitis-IVIG treatment reduces proinflammatory cytokine production. J Neuroimmunol 2004;150:139-144.
51. Gonzalez H, Sunnerhagen KS, Sjoberg I, etal. Intravenous immunoglobulin for post-polio syndrome: A randomised controlled trial. Lancet Neurol 2006;5:493-500.
52. Werhagen L, Borg K. Effect of intravenous immunoglobulin on pain in patients with post-polio syndrome. J Rehabil Med 2011;43:1038-1040.
53. Östlund G, Broman L, Werhagen L, etal. IVIG treatment in post-polio patients: Evaluation of responders. J Neurol 2012;259:2571-2578.
54. Farbu E, Rejkand T, Vik-Mo E, etal. Post-polio syndrome patients treated with intravenous immunoglobulin: A double-blinded randomized controlled pilot study. Eur J Neurol 2007;14:60-65.
55. Vincent A, Bien CG, Irani SR, etal. Autoantibodies associated with diseases of the CNS: New developments and future challenges. Lancet Neurol 2011;10:759-772.
56. Irani SR, Pettingill P, Kleopa KA, etal. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012;72:241-255.
57. Bennett DL, Vincent A. Autoimmune pain: An emerging concept. Neurology 2012;79:1080-1081.
58. Irani SR, Alexander S, Waters P, etal. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734-2748.
59. Breivik H, Collett B, Ventafridda V, etal. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333.
60. Bousfiha AA, Jeddane L, Ailal F, etal. Primary immunodeficiency diseases worldwide: More common than generally thought. J Clin Immunol 2013;33:1-7.
61. Waller C. Historical perspective on blood and plasma products, the stakeholders and the issues. In: Valverde JL, ed. Blood, Plasma and Plasma proteins: A Unique Contribution to Modern Health Care. Pharmaceuticals Policy and Law. Amsterdam, NL: IOS Press; 2006:7-19.
62. Farrugia A, Evers T, Falcou PF, etal. Plasma fractionation issues. Biologicals 2009;37:88-93.
63. Farrugia A, Robert P. Plasma protein therapies: Current and future perspectives. Best Pract Res Clin Haematol 2006;19:243-258.
64. Jacobson NM. The art of balanced production. In: Valverde JL, ed. Blood, Plasma and Plasma proteins: A Unique Contribution to Modern Health Care. Pharmaceuticals Policy and Law. Amsterdam, NL: IOS Press; 2006:81-87.
65. Dodel R, Rominger A, Bartenstein P, etal. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12:233-243.
66. Phillips CJ, Hughes DA. HTAs and rare diseases: How to assess their cost-effectiveness. In: Valverde JL, Prévot J, eds. Health Technology Assessments and Rare Diseases. Pharmaceuticals Policy and Law. Amsterdam, NL: IOS Press; 2011:161-165.
67. Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP. Blood 2012;119:5261-5264.